Results of 2026 Annual General Meeting

MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 20 November 2026: In accordance with ASX Listing Rule 3.13.2 and Section 251AA of the *Corporations Act 2001* (Cth), the attached information is provided in relation to the resolutions passed by the shareholders of Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") at its Annual General Meeting held on 20 November 2026.

About Alterity Therapeutics Limited

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is focused on developing disease modifying therapies for Parkinson's disease and related disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in Multiple System Atrophy (MSA), a rare and rapidly progressive neurodegenerative disease without an approved treatment. ATH434, the Company's lead asset, demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company's website at https://alteritytx.com.

Authorisation & Additional Information

This announcement was authorised by David Stamler, CEO of Alterity Therapeutics Limited.

Contacts:

Investors

Elyse Shapiro
ir@alteritytx.com

Remy Bernarda
Investor Relations Advisory Solutions
ir@alteritytx.com
+1 (415) 203-6386

Media

Melissa Tempra
NWR Communications
melissa@nwrcommunications.com.au

Casey McDonald
Tiberend Strategic Advisors, Inc.
cmcdonald@tiberend.com
+1 (646) 577-8520

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements.

Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled "Risk Factors" in the Company's filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company's drug components, including, but not limited to, ATH434, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection for the Company's intellectual property or trade secrets, the uncertainty of successfully enforcing the Company's patent rights and the uncertainty of the Company freedom to operate.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Results of Meeting

Alterity Therapeutics Limited

Annual General Meeting

Friday, 20 November 2026

Automic
GPO Box 5193, Sydney, NSW 2001
P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)
F +61 (0)2 8583 3040 E hello@automic.com.au
ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

		Proxy Votes (as at proxy voting close)				Poll Results (if applicable)			Results
Resolution	**Decided by Show of Hands (S) or Poll (P)**	**FOR**	**AGAINST**	**ABSTAIN**	**PROXY'S DISCRETION**	**FOR**	**AGAINST**	**ABSTAIN**	**OUTCOME**
1 Adoption of Remuneration Report	P	51,111,943 81.74%	11,097,688 17.75%	65,121	318,560 0.51%	51,439,594 79.34%	13,397,357 20.66%	65,121	-
2 Re-election of a Director - Peter Marks	P	52,639,232 83.87%	9,814,582 15.64%	19,763	311,075 0.50%	52,959,398 81.38%	12,114,251 18.62%	19,763	Carried
3 Re-election of a Director - Lawrence Gozlan	P	51,479,971 82.02%	10,967,175 17.47%	20,375	317,131 0.51%	53,884,198 82.81%	11,188,839 17.19%	20,375	Carried
4 Approval of 7.1A mandate	P	55,652,649 88.78%	5,774,920 9.21%	98,523	1,258,560 2.01%	56,920,300 87.58%	8,074,589 12.42%	98,523	Carried
5 Approval to issue Options to Peter Marks	P	48,467,891 77.57%	13,789,780 22.07%	107,467	228,174 0.37%	48,705,156 75.17%	16,089,449 24.83%	107,467	Carried
6 Approval to issue Options to Lawrence Gozlan	P	48,658,631 77.63%	13,784,324 21.99%	107,467	234,230 0.37%	48,901,952 75.25%	16,083,993 24.75%	107,467	Carried
7 Approval to issue Options to Julian Babarczy	P	48,642,587 77.61%	13,797,368 22.01%	110,467	234,230 0.37%	48,885,908 75.23%	16,097,037 24.77%	110,467	Carried
8 Approval to issue Options to Ann Cunningham	P	50,067,571 79.89%	12,372,312 19.74%	110,539	234,230 0.37%	52,388,897 80.62%	12,593,976 19.38%	110,539	Carried
9 Approval to issue Options to David Stamler	P	49,897,635 80.84%	11,600,956 18.79%	860,491	228,174 0.37%	50,125,809 78.29%	13,900,625 21.71%	860,491	Carried

		Proxy Votes (as at proxy voting close)				Poll Results (if applicable)			Results
Resolution	**Decided by Show of Hands (S) or Poll (P)**	**FOR**	**AGAINST**	**ABSTAIN**	**PROXY'S DISCRETION**	**FOR**	**AGAINST**	**ABSTAIN**	**OUTCOME**
10 Approval of potential termination benefits to David Stamler	P	48,226,076 78.17%	13,236,454 21.45%	1,089,321	232,801 0.38%	50,545,973 78.97%	13,458,118 21.03%	1,089,321	Carried
11 Confirmation of appointment of auditor	P	61,131,726 97.49%	1,254,588 2.00%	81,207	317,131 0.51%	63,535,953 97.73%	1,476,252 2.27%	81,207	Carried